Ikonisys to Present at AdvaMed 2008
Ikonisys, a leading provider of next-generation, cell-based diagnostic solutions, announced today that Paul White, Ikonisys president, will present at AdvaMed 2008: The MedTech Conference in Washington, D.C. this afternoon. During his presentation, Mr. White will discuss the research and advancements that the company has accomplished in the growing field of non-invasive, next-generation diagnostics. Additionally, he will discuss Ikonisys’ recent milestone, the launch of oncoFISH(R) cervical, a rare-cell based test for the early diagnosis of cervical cancer.
Additional panel details are as follows:
— Who: Ikonisys President Paul White
— What: Ikonisys overview including research, advancements and pipeline
— When: Tuesday, Sept. 23, 12:15 p.m. ET
— Where: AdvaMed 2008: The MedTech Conference, September 21 – 24, Marriott Wardman Park Hotel, Washington, D.C.
— URL: http://www.advamed2008.com/
AdvaMed 2008: The MedTech Conference is a three-day event that brings together medical technology business leaders, policy-makers, patient groups, financiers and service providers from around the world to actively discuss the business, political and financial matters that further the innovation of the industry.
About Ikonisys
Ikonisys is changing the practice of diagnostic medicine through its unique CellOptics(R) platform – an innovative combination of intelligent imaging, microscopy, biology and informatics – that enables Ikonisys to deliver diagnostic test solutions that are automated, innovative and integrated. By providing "walk away" automation solutions, Ikonisys enables reference labs, hospitals, research institutions and practice groups to both greatly expand their test volume capacity and standardize their diagnostic procedures. This will further enhance their ability to economically deliver accurate, fast and personalized results for early cancer diagnosis and monitoring, and genetic disorder screening to physicians and researchers.
In addition to automating existing FISH-based tests, the CellOptics platform enables Ikonisys to launch a stream of next-generation diagnostic tests that are based on the detection of rare cells in a practical, efficient and economical manner. These "signature" tests will include proprietary test specific reagents. The integration capabilities of the CellOptics platform provides for both the transfer of patient test data into a laboratory’s information systems – enabling the creation of more comprehensive patient medical records – as well as the potential to utilize these novel tests as companion diagnostics, which provides a path to fully realize the promise of personalized medicine.
In 2006, Ikonisys obtained FDA clearance for fastFISH(R) amnio, an imaging application for the Ikoniscope(R) that provides automated identification of numerical aberrations of chromosomes associated with common birth defects. Additionally, in early 2007, the company received FDA clearance for oncoFISH(R) bladder, an Ikoniscope application that helps in the initial diagnosis of bladder cancer.